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Abstract
Background: Sickle cell disease (SCD) is a chronic disease associated with high degrees of morbidity and
increased mortality. Health-related quality of life (HRQOL) among adults with sickle cell disease has not
been widely reported.
Methods: We administered the Medical Outcomes Study 36-item Short-Form to 308 patients in the Pain
in Sickle Cell Epidemiology Study (PiSCES) to assess HRQOL. Scales included physical function, physical
and emotional role function, bodily pain, vitality, social function, mental health, and general health. We
compared scores with national norms using t-tests, and with three chronic disease cohorts: asthma, cystic
fibrosis and hemodialysis patients using analysis of variance and Dunnett's test for comparison with a
control. We also assessed whether SCD specific variables (genotype, pain, crisis and utilization) were
independently predictive of SF-36 subscales, controlling for socio-demographic variables using regression.
Results: Patients with SCD scored significantly worse than national norms on all subscales except mental
health. Patients with SCD had lower HRQOL than cystic fibrosis patients except for mental health. Scores
were similar for physical function, role function and mental health as compared to asthma patients, but
worse for bodily pain, vitality, social function and general health subscales. Compared to dialysis patients,
sickle cell disease patients scored similarly on physical role and emotional role function, social functioning
and mental health, worse on bodily pain, general health and vitality and better on physical functioning.
Surprisingly, genotype did not influence HRQOL except for vitality. However, scores significantly
decreased as pain levels increased.
Conclusion: SCD patients experience health related quality of life worse than the general population, and
in general, their scores were most similar to patients undergoing hemodialysis. Practitioners should regard
their HRQOL as severely compromised. Interventions in SCD should consider improvements in health
related quality of life as important outcomes.
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Background
Functional status and health-related quality of life
(HRQOL) may be impaired in sickle cell disease (SCD)
due to morbid events, such as stroke, or other organ sys-
tem failures. The Cooperative Study of Sickle Cell Disease
(CSSD) found that morbid events such as strokes that
impaired function often preceded death in childhood [1-
3] Until recent decades, SCD was associated with chronic
childhood pain, organ failure and death in very early
adulthood. Treatment advances have now transformed
SCD into a chronic disease suffered by children and
adults. Frequently, patients surviving until adulthood
experience significant organ system damage that may
include stroke, pulmonary failure and pulmonary hyper-
tension, renal failure, congestive heart failure, leg ulcers,
and osteonecrosis of the femoral or humeral heads [2].
Children and adolescents with SCD report poor HRQOL
in qualitative studies using focus groups [4], and fare
worse in their HRQOL compared to controls on health
surveys [5] or on assessments of general physical, motor
and independent daily functioning [6,7]. Despite the con-
siderable evidence in children for reduced HRQOL in
SCD, few studies have evaluated the impact of this disease
on health related quality of life in adults [8-11].
The impact of this disease on HRQOL for adults may be
even greater than for children. Quality of life is deterio-
rated by episodic, debilitating pain associated with sub-
stantial analgesic use, frequent hospitalization for pain
episodes, and ultimately organ failure. Although SCD
related pain can often be managed by analgesics and opi-
oids, adults with SCD may be under-treated because clini-
cians suspect drug dependence in this population. This
provider bias may lead to reluctance by patients to seek
medical attention [12,13]. Further, HRQOL may be over-
estimated by providers that do not regularly care for
patients with SCD due to lack of understanding of the
severity of the painful crises and the potential impact on
function. Therefore, assessing the quality of life among a
US adult SCD population and providing comparisons
with HRQOL reported among comparable adults with
other chronic diseases may be an important method for
providing health care practitioners who care for these
patients a more objective perspective on the impact and
severity of this disease. In addition, quality of life in SCD
is important to describe because it amplifies the ability to
identify patients for whom potentially dangerous but
potent interventions such as hydroxyurea or bone marrow
transplantation is justified at an early stage.
Methods
Study description
The Pain in Sickle Cell Epidemology Study (PiSCES) is a
longitudinal cohort study of over 300 adult patients with
SCD designed to understand the relationship between
pain and response to pain. The emphasis is on potentially
mutable etiologic, and non-biologic variables. The PiS-
CES methods have been described in detail elsewhere
[14]. Briefly, we enrolled 308 adult patients with SCD
from July 2002 through August 2004. Baseline informa-
tion, laboratory data and daily pain diary data were col-
lected. Baseline data was collected at the time of
enrollment using a self-administered questionnaire which
included questions on demographics, health related qual-
ity of life, and other information including medical his-
tory and medication use. In addition to the survey
information, blood was obtained for genotyping and
urine specimens were collected to assess renal function.
As part of the PiSCES study, patients filled out daily dia-
ries for up to 6 months [14]. The diary was modeled after
the one used in the Multicenter Study of Hydroxyurea
[15]. Among other things, the diary asked patients to
report about the previous 24 hours: the worst sickle cell
pain intensity, on a scale from 0 (none) to 9 (unbearable),
whether or not they were in a sickle cell crisis, and
whether they had gone for an unscheduled physician visit,
ED visit or were hospitalized due to sickle cell pain.
Patient population
Patients were solicited for enrollment from across Vir-
ginia, but focused on the Richmond and Tidewater areas
of Virginia. Patients aged 16 years and older were eligible
for enrollment Patients identified as potentially eligible
for the study were invited and scheduled for an enroll-
ment visit, at which time informed consent was obtained.
The study, along with recruitment methods, was approved
by the VCU IRB.
Interested patients were then screened using the Mini
Mental Status Examination [16] to assure competency
(excluded if score less than 27) and the ability to provide
informed consent. Patents were compensated ten dollars
for the initial visit, when blood and urine specimens are
obtained, and the baseline survey was completed.
To assess the relative HRQOL in SCD patients, compari-
son groups from published reports representing three dif-
ferent cohorts of patients with chronic diseases including
asthma [17], cystic fibrosis [18] and hemodialysis [19]
patients were included. These comparison groups were
selected to be similar in age and gender to the PiSCES
cohort. The asthma sample consisted of 301 patients
whose mean age was 38 and 56% of whom were female.
The hemodialysis sample consisted of 1000 prevalent
cases with a mean age of 58 and of whom 50% were
female. Data regarding cystic fibrosis came from 223 ado-
lescents and adult subjects participating in a validation ofHealth and Quality of Life Outcomes 2005, 3:50 http://www.hqlo.com/content/3/1/50
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the quality of life instrument with a mean age of 25, and
54% female.
Analytic variables
The Medical Outcome Study 36 item Short Form (SF-36)
[20] is a generic measure of health related to functional
status and well being. The survey is not disease- or age-
specific and has been validated across a wide variety of
age, race and disease groups, including many chronic dis-
eases [20-22]. The SF-36 has high test-retest reliability, has
been shown to predict a number of poor outcomes [23],
has been compared with biological markers for their sen-
sitivity to change in severity of chronic illness [24], and
has been used as outcomes in clinical trials of chronic ill-
ness [25].
The SF-36 is multidimensional with subscales represent-
ing eight of the most important dimensions of HRQOL:
physical function, physical role functions, emotional role
functioning, bodily pain, vitality, general health, mental
health and social function. Subscales are measured on a
scale from 0 – 100 (with 0 being the worst and 100 the
best score). Values are available for specific age and gender
population subgroups for the US and other populations.
In addition to the chronic disease samples used for com-
parison, the normal values for age matched males and
females from the general US population are provided and
compared with our study population.
Sickle cell genotype (Sβ+ Thalasemia, Sßo Thalasemia, SC
and SS) is a known predictor of mortality and disease
severity. The CSSCD evaluated the natural history of 3578
patients ranging in age from newborns to age 66. Hospital
utilization due to pain varied according to genotype (SS =
0.8 episodes/pt/yr., Sßo Thalasemia = 1.0 episodes/pt/yr.,
SC and Sß+ Thalasemia = 0.4 episodes/pt/yr) [1]. Geno-
type was also a predictor of the age at death [2]. Further,
among patients over the age of 20, the hospital utilization
rate due to pain was correlated with mortality over the
years [2]. For this study, genotype was obtained either
directly from the blood specimen obtained from the
patient at enrollment or from the patient's medical record.
Since there were few patients with Sβ+ Thalasemia and Sßo
Thalasemia, for purposes of analyses, two groups were
defined. The more severe genotype grouping included SS
and Sßo Thalasemia, the less severe group included SC and
Sβ+ Thalasemia,
We used three calculated variables from the diary for this
study. Mean daily pain was calculated as the sum of the
pain intensity for all diary days, divided by the total
number of days the diary was completed. The percentage
of days for which a crisis was marked on the diary was cal-
culated as 100*the number of days with crisis marked,
divided by the total number of days the diary was com-
pleted. Percentage of days on which there was utilization
was constructed similarly, with utilization consisting of
either an unscheduled clinic visit, an ED visit or an over-
night hospitalization. Since these latter two variable was
very skewed, with many having no crisis or utilization, for
analysis the diary variables were divided into 3 categories
of roughly equal size (coded 1, 2, 3): Percent of days with
self-reported crises: 0, 0.1–10, 10+; Percent of days with
utilization: 0, 0.1–3, 3+.
Statistical methods
Means and standard deviations are presented. Compari-
son values were created from MOS national norms data by
using a weighted average of age-gender specific values,
with the weights equal to the proportion of the PiSCES
sample in that age group. Subscales for the PiSCES cohort
were compared to national norms with a t-test. Analysis of
variance was used as an overall test for equality of each
subscale across chronic disease cohorts. When the overall
F test was significant, Dunnett's test was used to compare
each of the chronic diseases to the mean for the PiSCES
cohort. To determine whether SCD-specific variables were
independently predictive of HRQOL, we used multiple
linear regression, controlling for socio-demographic vari-
ables (age, gender, education). SCD-specific variables
included genotype, mean pain, and percent days of diary
days reporting crisis and utilization. These analyses were
Table 1: Demographic description of PiSCES cohort
Variable Frequency (percent)
Gender
Male 122 (39.6)
Female 186 (60.4)
Education
<High school 41 (13.4)
High School grad 116 (37.9)
Some college 110 (35.9)
College Grad 39 (12.7)
Age group
16–24 79 (25.6)
25–34 92 (29.9)
35–44 82 (26.9)
45–54 42 (13.6)
55–64 12 (3.9)
Marital Status
Married 67 (21.8)
Never married 198 (64.5)
Divorced/separated/widowed 42 (13.7)
Genotype
SS 206 (66.9)
Sßo Thalasemia 8 (2.6)
SC 75 (4.3)
Sβ+ Thalasemia 10 (3.2)
Unknown 9 (2.9)Health and Quality of Life Outcomes 2005, 3:50 http://www.hqlo.com/content/3/1/50
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limited to patients who had returned at least 30 diaries.
This reduced the sample from 308 to 226. Three addi-
tional subjects were excluded from regression analyses
because they lacked information on genotype. Analysis
used SAS 8.2 for UNIX.
Results
Table 1 describes the PiSCES cohort. The mean age was
33, and ranged from 16 to 64. There were more women
than men in the study (60.4% vs 39.6), 48.6% attended
college. Only 21.8% of subjects were currently married.
Table 2 has means and standard deviations for the 8 SF-36
subscales for the PiSCES cohort, separately for men and
women, along with the age-adjusted national norms by
gender. When the gender stratified PiSCES cohort was
compared with national norms, values were significantly
lower for all subscales (P < 0.0001) with one exception –
the mental health scale was not significantly different
from the national norm (men: p = 0.670, women: p =
0.102).
Table 3 has means and standard deviations of the 8 SF-36
subscales for the PiSCES cohort along with cohorts of
patients with three other chronic diseases – asthma, cystic
fibrosis and hemodialysis. There were significant
differences (P < 0.0001) amongst cohorts for all subscales
except mental health (p = 0.0582), which was marginal.
Patients with SCD (PiSCES cohort) reported significantly
worse HRQOL on all subscales (p < 0.05) except mental
health as compared to adolescents and adults with cystic
fibrosis. They had similar reported quality of life as
asthma patients regarding physical function and role
function (both physical and emotional), and mental
health, but scored lower for the bodily pain, vitality, social
function and general health subscales. When compared to
patients on hemodialysis, SCD patients reported similar
low scores for physical and emotional role function and
social function. They also did not differ on the mental
health subscale (p > 0.15). SCD patients had lower scores
for the pain, vitality and general health subscales (P <
0.01), but reported a higher score for the physical func-
tion subscale compared with the hemodialysis cohort.
Multiple regressions were performed to look at the rela-
tionship of SCD specific variables (genotype, mean pain,
percent of diary days subjects reported crisis and percent
of diary days subjects reported utilization) and SF-36 sub-
scales. Socio-demographic variables (age, gender, number
of years of education) were included in the models as cov-
ariates. Results are in Table 4. For each subscale, mean
SCD pain was highly predictive (p < 0.0001 for all sub-
scales except p = 0.0396 for mental health). The more
SCD pain a subject experienced, the worse the reported
quality of life. One unit increase in pain (on a 0–9 scale)
was associated with an approximate decrease of 1.4 (men-
tal health) to 6 (both role functions) units on an SF-36
subscale. Percentage of days with crisis was an independ-
ent predictor of bodily pain (p = 0.0109), with an approx-
imate 6 point decrease in bodily pain score for each
increase in crisis category. Genotype was also an inde-
pendent predictor of vitality (p = 0.0161), with SS/Sßo
Thalasemia being associated with better vitality. No other
variables were independent predictors of SF-36 subscales.
Discussion
In general, SCD patients experience a poor health related
quality of life. Except for mental health, the SF-36 subscale
values were considerably lower than norms of the general
US population. They reported a HRQOL that was equal to
or poorer than patients with other significant chronic con-
ditions in many domains. Similar to patients with SCD,
until somewhat recently, patients with cystic fibrosis
rarely lived until adulthood, marking this as a disease with
Table 2: SF-36 – PiSCES cohort vs National Norms (Mean ± standard deviation)
Male Female
PiSCES Norm PiSCES Norm
Physical Function 66.4 ± 24.1 92.3 ± 15.5 59.9 ± 25.1 87.4 ± 19.7
Role-Physical 40.1 ± 38.7 90.5 ± 24.0 38.6 ± 39.9 83.8 ± 31.5
Bodily Pain 50.8 ± 28.6 79.6 ± 21.1 45.2 ± 26.0 77.3 ± 22.1
General Health 42.7 ± 22.3 77.1 ± 17.3 37.0 ± 21.7 73.9 ± 19.0
Vitality 50.4 ± 22.5 64.9 ± 19.2 37.6 ± 21.0 59.2 ± 20.6
Social Function 62.3 ± 27.6 86.6 ± 19.9 62.4 ± 24.8 82.8 ± 22.1
Role-emotional 62.7 ± 43.1 85.0 ± 29.4 54.7 ± 42.8 80.7 ± 33.1
Mental Health 75.3 ± 20.7 76.4 ± 16.8 69.2 ± 20.0 72.8 ± 18.3
P < 0.0001 comparing PiSCES to SF-36 for all subscales, except MH, female: p = 0.102 and male: p = 0.670;Health and Quality of Life Outcomes 2005, 3:50 http://www.hqlo.com/content/3/1/50
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significant sequelae and high mortality. It is interesting,
then, to see that quality of life of adult survivors of this
chronic disease, even though impaired, was comparable
to national norms, and was generally far superior than
that reported by adults with SCD. Of the three chronic
conditions selected for comparison, the PiSCES cohort
had HRQOL patterns most similar to that of patients
undergoing chronic hemodialysis.
That SCD patients did not report poorer mental health
and well being than the general US population is
consistent with findings for many medical conditions. In
1978 Brickman, et al [26] presented a famous result show-
ing that lottery winners are not much happier than para-
plegics. Since that time many studies have confirmed
similar results, that while people who are sick may report
their health as being worse than the general population,
they appear to have similar well-being. Not only was it
true of the asthma, dialysis and cystic fibrosis cohorts pre-
sented here, but similar results have been shown for peo-
ple with other chronic diseases both in the US and other
countries [21,22,27].
It has been suggested that the fact that many people with
chronic diseases report good psychological well being
could be a result of increased social support, lack of other
stressors, or a "response shift" associated with the manag-
ing their chronic disease [27]. The "response shift" could
be a result of a scale recalibration, a change in the patient's
values, or a reconceptualization of their mental health
and well-being [28,29] in order to accommodate their ill-
ness. Riis et al [30] dispute the idea of scale recalibration,
proposing instead that people have adapted to their ill-
ness or situation.
Table 3: SF-36: Comparison of PiSCES sample with other chronic disease cohorts (mean ± standard deviation)
PiSCES Hemo-Dialysis Cystic Fibrosis Asthma ANOVA F value†
N = 308 N = 1000 N = 223 N = 241
Physical Function 62.4 ± 24.9 44.3 ± 27.8* 76.3 ± 24.0* 63.2 ± 21.4 121.3
Role-Physical 39.2 ± 39.4 39.7 ± 40.4 72.9 ± 38.4* 38.7 ± 39.9 74.7
Bodily Pain 47.4 ± 27.2 60.4 ± 29.1* 82.2 ± 21.3* 67.2 ± 23.2* 49.5
General Health 39.2 ± 22.1 50.0 ± 22.4* 43.4 ± 23.7* 57.9 ± 19.0* 37.9
Vitality 42.7 ± 22.5 46.5 ± 22.3* 58.4 ± 23.1* 48.2 ± 20.8* 23.3
Social Function 63.5 ± 25.2 66.0 ± 29.9 80.4 ± 23.8* 72.1 ± 22.2* 21.3
Role-emotional 57.8 ± 43.1 58.2 ± 42.7 77.0 ± 36.9* 63.3 ± 41.5 13.1
Mental Health 71.6 ± 20.4 69.7 ± 21.6 73.7 ± 18.1 70.7 ± 18.4 2.56
†Numerator degrees of freedom are 3, denominator degrees of freedom are N-4;
*p < 0.0001 compared to PiSCES cohort
Table 4: Results of regression of SCD-specific variables on SF-36 subscales, controlling for socio-demographic variables1 (regression 
coefficients ± standard error)
Genotype2 Mean pain Proportion Days with 
Crisis3
Proportion Days with 
Utilization4
Physical Function -5.01 ± 3.30 -4.55 ± 0.72** -0.42 ± 2.12 3.51 ± 1.97
Role-Physical -1.62 ± 5.73 -6.12 ± 1.27** -0.91 ± 3.70 2.75 ± 3.39
Bodily Pain 0.14 ± 3.57 -4.41 ± 0.79** -5.93 ± 2.31* -0.59 ± 2.13
General Health 3.52 ± 3.19 -3.34 ± 0.71** -1.31 ± 2.09 -1.44 ± 1.92
Vitality 6.43 ± 3.27* -3.54 ± 0.72** 0.55 ± 2.10 3.06 ± 1.94
Social Function 3.16 ± 3.77 -4.27 ± 0.82** -3.28 ± 2.44 1.93 ± 2.25
Role-emotional 7.06 ± 6.27 -5.81 ± 1.39** 2.30 ± 4.09 2.12 ± 3.71
Mental Health 4.23 ± 3.14 -1.44 ± 0.69* -1.53 ± 2.02 0.35 ± 1.87
1controlling for age, gender, years of education
2SS and Sßo Thalasemia vs SC and Sß+ Thalasemia
3Percent of days with crises: 0, 0.1–10,10+ (coded 1,2,3)
4Percent of days with utilization: 0, 0.1–3, 3+ (coded 1,2,3)
*p ≤ 0.05; **p < 0.0001Health and Quality of Life Outcomes 2005, 3:50 http://www.hqlo.com/content/3/1/50
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Heady and Wearing [31] propose that there is a baseline
level of mood or well-being that people have to which
they return after events cause them to move from that
baseline. This is supported by a twin study indicating that
most variation in well-being is due to variations in genet-
ics, not life circumstances [32]. That would suggest that,
while perhaps people with SCD may temporarily report
poorer well-being associated with high levels of pain or
other disease sequalae, most often they would report a
baseline well-being similar to that of others.
Despite the similar level of well-being in SCD patients
compared with both norms and patients with other
chronic diseases, patients with SCD experience significant
decrements in other important aspects of HRQOL. This is
supported in a study of adult SCD patients in the UK,
where Anie et al, found their population also had much
lower HRQOL scores than general UK population norms.
Further, the patients in this study had reported HRQOL
similar to patients with arthritis due to hereditary
haemochromatisis, another chronic disease [9]. Patients
in the PiSCES cohort reported somewhat lower general
health and higher mental health scores than Anie et al
found. This may result in part from differences in the two
cohorts, including their relative access to health care in the
two settings.
Surprisingly, HRQOL was not associated with genotype
except for the vitality subscale. However there was a strong
association with reduced HRQOL and pain levels, and, for
a few subscales, there was a trend with increasing levels of
utilization. The relationship between genotype severity
and HRQOL may have been mediated by these variables,
particularly pain. Anie et al [9] also found a relationship
between pain and some subscales of the SF-36 (physical
and social functions, mental and general health) but
found no significant association with utilization meas-
ures. Whether the more severe manifestations of the dis-
ease cause the poorer quality of life, or patients who
report poorer quality of life suffer more and use more
health care cannot be determined from this study.
It is unclear why the direction of the statistically signifi-
cant association between vitality for SS/Sßo Thalasemia vs
SC/Sß+ Thalasemia is opposite of what would be expected,
with the more severe genotype being associated with bet-
ter vitality. Even the nonsignificant relationships between
genotype and the other HRQOL subscales in these regres-
sions were in the same direction, except for physical func-
tioning. Similarly, increased utilization tended to be
associated, albeit nonstatistically with better HRQOL
scores for most subscales These counter-intuitive findings
should be explored by other SCD researchers.
There are several limitations of this study. First, this study
enrolled patients from only one state, so may not be rep-
resentative of the entire US SCD population. When com-
paring to populations with chronic disease, the gender
and age distributions were not ideally matched. In partic-
ular, the PiSCES cohort, at a mean age of 33, is signifi-
cantly younger than the dialysis comparison group
However, since SF-36 subscale scores tend to decrease
with age, the fact that these younger patients with SCD
had worse HRQOL scores on some subscales than an
older hemodialysis cohort is even more alarming
Conclusion
Practitioners caring for adult SCD patients should regard
their quality of life as severely compromised, with scores
that are most similar to hemodialysis patients in our com-
parison of other chronic diseases. Although reducing mor-
tality is of paramount importance among SCD patients,
future interventions should consider improving health
related quality of life as a clinical endpoint.
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